Eye care composition containing ergothioneine as well as preparation method and application thereof
By using specific proportions of ingredients such as ergothioneine, taurine, sodium hyaluronate and vegetable essential oil in eye care compositions, the problems of single and insufficient stability of existing eye wash are solved, and multiple functions are achieved The combination of both and high stability provides effective relief of visual fatigue, eye itching and dryness.
Patent Information
- Application Number
- CN202411015027.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-26
- Publication Date
- 2024-11-15
- Estimated Expiration
- 2044-07-26
AI Technical Summary
The existing eye wash is relatively single, which cannot meet the needs of consumers for a variety of eye symptoms. It also has stability and irritation problems, making it difficult to have multiple effects such as anti-inflammatory, anti-fatigue, and moisturizing.
Using compositions containing ergothioneine, taurine, sodium hyaluronate, plant essential oils and antibacterial agents, a high stability, anti-inflammatory, relieve visual fatigue, and the eyes are formed through specific proportions and preparation methods. Eye care compositions that are itchy, dry eyes and have good moisturizing effects.
It significantly improves the antioxidant, anti-fatigue and antibacterial effects of the eye care composition, and achieves the combination of multiple functions, ensuring the stability and safety of the product.
Smart Images

Figure BDA0004965458950000101 
Figure BDA0004965458950000111 
Figure BDA0004965458950000121
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of medicines, and in particular to an eye care composition containing ergothioneine, a preparation method thereof and an application thereof. Background Art
[0002] Frequent use of electronic products can easily cause visual fatigue, dry and sore eyes, weaken the antioxidant defense system of the eyes, cause vision loss, blurred vision and other eye diseases. Eyewash is added with pure natural active substances, and is prepared with purified water or distilled water and inorganic salts to form a solution suitable for the human body. It cleans and cares for the eyes, relieves eye fatigue, keeps the eyes clean, relieves some eye diseases, and repairs some minor physical damage in the eyes. It can also stimulate the microcirculation of the eyes, meet the nutrient needs of the eye skin, and improve the dark circles caused by fatigue, staying up late and poor sleep. It is deeply loved by consumers.
[0003] Chinese patent CN 116889599 A discloses a blueberry eyewash and its preparation method in the field of eyewash technology. Each 1000mL eyewash is prepared from the following raw materials: 60-80g blueberries, 80-100g isatis indigo leaves, 20-40g mulberry leaves, 2-3g complex vitamins, 0.2-0.25g sodium hyaluronate, and the complex vitamins are any two of vitamin B6, vitamin B12, vitamin A, and vitamin E. The eyewash is prepared by mixing blueberries, isatis indigo leaves, mulberry leaves, complex vitamins, and sodium hyaluronate. The raw material cost is low, and the local administration method is adopted to directly reach the site of action, with fast absorption speed and obvious use effect. However, its effect is only biased towards soothing dryness, and it does not have the effects of anti-fatigue and anti-inflammatory.
[0004] Chinese patent CN 114099551 B discloses a composition for relieving visual fatigue and moistening the eyes, which contains glycerol glucoside, zinc sulfate, tea polyphenols, taurine, dipotassium glycyrrhizinate, menthol, borneol and other main ingredients. It can be used in eye sprays and eyewashes, and has the effects of relieving visual fatigue, eye itching, dryness around the eyes, dry eyes, improving vision, etc., and has good moisturizing effect, is natural, safe and non-irritating, and has good application prospects. However, its ingredients are relatively complex and no stability test has been conducted.
[0005] Chinese patent CN 114949035 A discloses an eyewash for preventing dry eye and its preparation method, which is prepared from the following raw materials: 4-7 mg taurine, 3-7 mg borneol, 60-80 g cornflower, 80-100 g isatis leaf, 20-40 g mint, 20-30 g vitamin A, 6-8 mL honey, 6-8 mL pearl liquid. It provides a safe, effective and easy-to-use ophthalmic drug preparation for the clinical treatment of dry eye. The product is only effective for dry eye, which is relatively single and cannot meet the needs of consumers for multiple eye symptoms.
[0006] On the one hand, most common eyewash care products on the market can only clean the eyes, and most of the ingredients are chemical drugs, which are very irritating to the eyes and will cause side effects if used for a long time. On the other hand, eyewashes or eye drops with anti-inflammatory, anti-allergic or vasoconstrictive functions usually use drugs such as antibiotics, which have strong side effects, can cause discomfort to normal people, and are highly irritating to the eyeballs. Furthermore, the efficacy of existing eyewashes is usually relatively single, and is only effective for a certain eye symptom, which cannot meet the needs of consumers. Therefore, it is urgent to develop an eyewash with natural and mild ingredients, multiple functions and good stability.
[0007] Based on this, the researchers of the present invention have developed an eye care composition containing ergothioneine and a preparation method thereof, and obtained an eye wash liquid with high stability, anti-inflammatory, and good moisturizing effect for relieving visual fatigue, eye itching, dry eyes by optimizing the formula and ratio. Summary of the invention
[0008] In view of the above problems, the present invention provides an eye care composition containing ergothioneine and a preparation method thereof. The composition comprises ergothioneine, taurine, sodium hyaluronate, plant essential oil, an antibacterial agent and an osmotic pressure regulator. Through the synergistic effect of each component and a specific ratio, an eye care composition containing ergothioneine is obtained, which has high stability, anti-inflammatory effect, can relieve visual fatigue, eye itching, dry eyes and good moisturizing effect.
[0009] To achieve the above purpose, the technical solution adopted by the present invention is as follows:
[0010] On the one hand, the present invention provides an eye care composition containing ergothioneine, comprising the following components: ergothioneine, taurine, sodium hyaluronate, plant essential oil, terephthalic acid, an osmotic pressure regulator and water for injection.
[0011] Preferably, the mass ratio of ergothioneine, taurine and terephthalodiboric acid is 70-120:190-210:1; further preferably, the mass ratio of ergothioneine, taurine and terephthalodiboric acid is 90-100:190-250:1.
[0012] Preferably, the mass ratio of taurine, sodium hyaluronate and plant essential oil is 10-25:1-10:1; further preferably, the mass ratio of taurine, sodium hyaluronate and plant essential oil is 16-20:4-7:1.
[0013] Preferably, the eye care composition containing ergothioneine comprises the following components in parts by weight: 0.01-1 part of ergothioneine, 0.1-5 parts of taurine, 0.05-0.4 parts of sodium hyaluronate, 0.03-0.06 parts of plant essential oils, 0.001-0.004 parts of terephthalic acid and 0.1-0.5 parts of osmotic pressure regulators, and water for injection makes up 100 parts by weight.
[0014] Preferably, the eye care composition containing thioneine comprises the following components in parts by weight: 0.25-0.42 parts of thioneine, 0.6-1.2 parts of taurine, 0.2-0.4 parts of sodium hyaluronate, 0.03-0.06 parts of plant essential oils, 0.001-0.004 parts of terephthalic acid and 0.1-0.5 parts of osmotic pressure regulators, and water for injection makes up 100 parts by weight.
[0015] Further preferably, the eye care composition containing thioneine comprises the following components in parts by weight: 0.3-0.4 parts of thioneine, 0.65-1.0 parts of taurine, 0.22-0.38 parts of sodium hyaluronate, 0.035-0.055 parts of plant essential oils, 0.002-0.004 parts of terephthalic acid and 0.2-0.5 parts of osmotic pressure regulators, and water for injection makes up 100 parts by weight.
[0016] More preferably, the eye care composition containing ergothioneine comprises the following components in parts by weight: 0.3-0.35 parts of ergothioneine, 0.7-0.8 parts of taurine, 0.22-0.3 parts of sodium hyaluronate, 0.04-0.05 parts of plant essential oils, 0.003-0.004 parts of terephthalic acid and 0.3-0.5 parts of osmotic pressure regulators, and the injection water is supplemented to 100 parts by weight.
[0017] Preferably, the eye care composition containing ergothioneine further comprises a pH regulator.
[0018] Preferably, the pH of the eye care composition containing ergothioneine is 5-7.5.
[0019] Preferably, the pH adjuster is selected from at least one of a citrate buffer and a borate buffer; more preferably, the pH adjuster is a citrate buffer.
[0020] Preferably, the plant essential oil is selected from at least one of rose essential oil, chamomile essential oil and peppermint essential oil; further preferably, the plant essential oil is selected from at least one of chamomile essential oil and peppermint essential oil; more preferably, the plant essential oil is chamomile essential oil and peppermint essential oil.
[0021] Preferably, the mass ratio of the chamomile essential oil to the peppermint essential oil is 1-6:2-4; further preferably, the mass ratio of the chamomile essential oil to the peppermint essential oil is 4-6:2-3; more preferably, the mass ratio of the chamomile essential oil to the peppermint essential oil is 5:2.
[0022] Preferably, the osmotic pressure regulator is selected from at least one of sodium chloride, potassium chloride, sorbitol, borax and boric acid; further preferably, the osmotic pressure regulator is selected from at least one of sodium chloride and potassium chloride; more preferably, the osmotic pressure regulator is selected from sodium chloride.
[0023] On the other hand, the present invention also provides a method for preparing the above-mentioned eye care composition containing ergothioneine, comprising the following steps:
[0024] S1: Mix sodium hyaluronate and water for injection to obtain solution A;
[0025] S2: Solution A is mixed with taurine, ergothioneine and terephthaloylboric acid, and the pH is adjusted to 5-7.5 to obtain solution B;
[0026] S3: Solution B is mixed with plant essential oil, and an osmotic pressure regulator is added to adjust the osmotic pressure to 250-350 mOsm / (Kg·H2O), and the mixture is filtered and sterilized, and packaged.
[0027] Preferably, the mixing temperature in S1 is 75-85°C; more preferably, the mixing temperature is 80°C.
[0028] Preferably, the mixing described in S1 is stirring.
[0029] Preferably, the mixing temperature in S2 is 35-45°C; further preferably, the mixing temperature in S2 is 35°C.
[0030] Preferably, the mixing described in S2 can be selected from at least one of stirring and ultrasound; further preferably, the mixing described in S2 is ultrasound.
[0031] Preferably, the mixing temperature in S3 is 30-35°C; further preferably, the mixing temperature in S3 is 30°C.
[0032] Preferably, the mixing in S3 can be selected from at least one of stirring and ultrasound; further preferably, the mixing in S3 is stirring.
[0033] In yet another aspect, the present invention also provides the use of the above-mentioned eye care composition containing ergothioneine in eye care.
[0034] Compared with the prior art, the present invention has the following beneficial effects:
[0035] 1. The present invention has found in research that thioneine, taurine and terephthaloyl boric acid have a synergistic effect in improving antioxidant effects, especially under the specific ratio of the technical solution of the present invention, the antioxidant property of the eye care composition containing thioneine is significantly improved;
[0036] 2. The present invention has found in the study that taurine, sodium hyaluronate and plant essential oil have a synergistic effect in soothing eyes and anti-fatigue effects, especially under the specific ratio of the technical solution of the present invention, the anti-fatigue effect of the eye care composition containing ergothioneine is significantly improved;
[0037] 3. The present invention has found in the study that taurine and terephthaloyl boric acid have a synergistic effect in improving the antibacterial effect, especially under the specific ratio of the technical solution of the present invention, the antibacterial effect of the eye care composition containing ergothioneine is significantly improved;
[0038] 4. The technical solution of the present invention obtains an eye care composition containing ergothioneine with high stability, anti-inflammatory, and good moisturizing effect for relieving visual fatigue, eye itching, dry eyes, and good moisturizing effect through specific components and ratios. DETAILED DESCRIPTION
[0039] In order to make the technical means, creative features, purpose and effect of the present invention easy to understand, the present invention is further explained below in conjunction with specific embodiments, but the following embodiments are only preferred embodiments of the present invention, not all. Based on the embodiments in the implementation mode, other embodiments obtained by those skilled in the art without making creative work all belong to the protection scope of the present invention. It is worth noting that the raw materials used in the present invention are all common commercial products, and their sources are not specifically limited. The technology and scientific terms used in the embodiments have the meanings commonly understood by those of ordinary skill in the art to which the present invention belongs.
[0040] Example 1
[0041] 1) Components
[0042] The invention comprises the following components in parts by weight: 0.35 parts of ergothioneine, 0.75 parts of taurine, 0.25 parts of sodium hyaluronate, 0.03 parts of chamomile essential oil, 0.012 parts of peppermint essential oil, 0.0036 parts of terephthalic acid and 0.44 parts of sodium chloride, and water for injection is supplemented to 100 parts by weight.
[0043] 2) Preparation
[0044] S1: Dissolve sodium hyaluronate and water for injection at 80°C under stirring to obtain solution A;
[0045] S2: Solution A, taurine, ergothioneine and terephthaloylboric acid were ultrasonically treated at 35°C for 20 min, and an appropriate amount of citrate buffer was added to adjust the pH to 5-7.5 to obtain solution B;
[0046] S3: Stir solution B and plant essential oil at 30°C to mix evenly, add sodium chloride to adjust the osmotic pressure to 310mOsm / (Kg·H2O), filter and sterilize, and package to obtain.
[0047] Example 2
[0048] Compared with Example 1, only the components were changed, specifically:
[0049] 1) Components
[0050] The invention comprises the following components in parts by weight: 0.12 parts of ergothioneine, 0.19 parts of taurine, 0.05 parts of sodium hyaluronate, 0.021 parts of chamomile essential oil, 0.009 parts of peppermint essential oil, 0.001 parts of terephthalic acid and 0.5 parts of sodium chloride, and water for injection is supplemented to 100 parts by weight.
[0051] The remaining operations are the same as those in Example 1.
[0052] Example 3
[0053] Compared with Example 1, only the components were changed, specifically:
[0054] 1) Components
[0055] The invention comprises the following components in parts by weight: 0.4 parts of ergothioneine, 1.0 parts of taurine, 0.4 parts of sodium hyaluronate, 0.043 parts of chamomile essential oil, 0.017 parts of peppermint essential oil, 0.004 parts of terephthalic acid and 0.1 parts of sodium chloride, and water for injection is supplemented to 100 parts by weight.
[0056] The remaining operations are the same as those in Example 1.
[0057] Comparative Example 1
[0058] Compared with Example 1, only the component is changed, thioneine is replaced by taurine, specifically:
[0059] The composition comprises the following components in parts by weight: 1.1 parts of taurine, 0.25 parts of sodium hyaluronate, 0.03 parts of chamomile essential oil, 0.012 parts of peppermint essential oil, 0.0036 parts of terephthalic acid and 0.44 parts of sodium chloride, and water for injection is supplemented to 100 parts by weight.
[0060] The remaining operations are the same as those in Example 1.
[0061] Comparative Example 2
[0062] Compared with Example 1, only the component is changed, thioneine is replaced by terephthaloyl boric acid, specifically:
[0063] The composition comprises the following components in parts by weight: 0.3536 parts of terephthalic acid, 0.75 parts of taurine, 0.25 parts of sodium hyaluronate, 0.03 parts of chamomile essential oil, 0.012 parts of peppermint essential oil and 0.44 parts of sodium chloride, and the amount of water for injection is supplemented to 100 parts by weight.
[0064] The remaining operations are the same as those in Example 1.
[0065] Comparative Example 3
[0066] Compared with Example 1, only the components are changed, taurine is used instead of terephthalic acid, specifically:
[0067] The invention comprises the following components in parts by weight: 0.35 parts of ergothioneine, 0.7536 parts of taurine, 0.25 parts of sodium hyaluronate, 0.03 parts of chamomile essential oil, 0.012 parts of peppermint essential oil and 0.44 parts of sodium chloride, and water for injection is supplemented to 100 parts by weight.
[0068] The remaining operations are the same as those in Example 1.
[0069] Comparative Example 4
[0070] Compared with Example 1, only the components are changed, and dipotassium glycyrrhizinate is used instead of terephthalic acid, specifically:
[0071] The invention comprises the following components in parts by weight: 0.35 parts of ergothioneine, 0.75 parts of taurine, 0.25 parts of sodium hyaluronate, 0.03 parts of chamomile essential oil, 0.012 parts of peppermint essential oil, 0.0036 parts of dipotassium glycyrrhizinate and 0.44 parts of sodium chloride, and water for injection is supplemented to 100 parts by weight.
[0072] The remaining operations are the same as those in Example 1.
[0073] Comparative Example 5
[0074] Compared with Example 1, only the components are changed, and terephthalic acid is replaced by parabens, specifically:
[0075] The invention comprises the following components in parts by weight: 0.35 parts of ergothioneine, 0.75 parts of taurine, 0.25 parts of sodium hyaluronate, 0.03 parts of chamomile essential oil, 0.012 parts of peppermint essential oil, 0.0036 parts of parabens and 0.44 parts of sodium chloride, and water for injection is supplemented to 100 parts by weight.
[0076] The remaining operations are the same as those in Example 1.
[0077] Comparative Example 6
[0078] Compared with Example 1, only the components are changed, and benzalkonium chloride is used instead of terephthalic acid, specifically:
[0079] The invention comprises the following components in parts by weight: 0.35 parts of ergothioneine, 0.75 parts of taurine, 0.25 parts of sodium hyaluronate, 0.03 parts of chamomile essential oil, 0.012 parts of peppermint essential oil, 0.0036 parts of benzalkonium chloride and 0.44 parts of sodium chloride, and water for injection is supplemented to 100 parts by weight.
[0080] The remaining operations are the same as those in Example 1.
[0081] Comparative Example 7
[0082] Compared with Example 1, only the components are changed, and thimerosal is used instead of terephthaloyl diboric acid, specifically:
[0083] The invention comprises the following components in parts by weight: 0.35 parts of ergothioneine, 0.75 parts of taurine, 0.25 parts of sodium hyaluronate, 0.03 parts of chamomile essential oil, 0.012 parts of peppermint essential oil, 0.0036 parts of thimerosal and 0.44 parts of sodium chloride, and water for injection is supplemented to 100 parts by weight.
[0084] The remaining operations are the same as those in Example 1.
[0085] Comparative Example 8
[0086] Compared with Example 1, only the components are changed, and sodium hyaluronate is used instead of taurine, specifically:
[0087] The invention comprises the following components in parts by weight: 0.35 parts of ergothioneine, 1 part of sodium hyaluronate, 0.03 parts of chamomile essential oil, 0.012 parts of peppermint essential oil, 0.0036 parts of terephthalic acid and 0.44 parts of sodium chloride, and water for injection is supplemented to 100 parts by weight.
[0088] The remaining operations are the same as those in Example 1.
[0089] Comparative Example 9
[0090] Compared with Example 1, only the components are changed, and sodium hyaluronate is used instead of plant essential oil, specifically:
[0091] The invention comprises the following components in parts by weight: 0.35 parts of ergothioneine, 0.75 parts of taurine, 0.292 parts of sodium hyaluronate, 0.0036 parts of terephthalic acid and 0.44 parts of sodium chloride, and water for injection is supplemented to 100 parts by weight.
[0092] The remaining operations are the same as those in Example 1.
[0093] Comparative Example 10
[0094] Compared with Example 1, only the components are changed, and chamomile essential oil is used instead of peppermint essential oil, specifically:
[0095] The invention comprises the following components in parts by weight: 0.35 parts of ergothioneine, 0.75 parts of taurine, 0.25 parts of sodium hyaluronate, 0.042 parts of chamomile essential oil, 0.0036 parts of terephthalic acid and 0.44 parts of sodium chloride, and water for injection is supplemented to 100 parts by weight.
[0096] The remaining operations are the same as those in Example 1.
[0097] Comparative Example 11
[0098] Compared with Example 1, only the components are changed, and the plant essential oil is removed, specifically:
[0099] The invention comprises the following components in parts by weight: 0.35 parts of ergothioneine, 0.75 parts of taurine, 0.25 parts of sodium hyaluronate, 0.0036 parts of terephthalic acid and 0.44 parts of sodium chloride, and water for injection is supplemented to 100 parts by weight.
[0100] The remaining operations are the same as those in Example 1.
[0101] Comparative Example 12
[0102] Compared with Example 1, only the group distribution ratio is changed, specifically:
[0103] The invention comprises the following components in parts by weight: 0.1 parts of ergothioneine, 1.5 parts of taurine, 0.05 parts of sodium hyaluronate, 0.11 parts of chamomile essential oil, 0.01 parts of peppermint essential oil, 0.0056 parts of terephthalic acid and 0.060 parts of sodium chloride, and water for injection is supplemented to 100 parts by weight.
[0104] The remaining operations are the same as those in Example 1.
[0105] Comparative Example 13
[0106] Compared with Example 1, only the preparation method is changed, specifically:
[0107] The components are the same as those in Example 1;
[0108] preparation:
[0109] Ergot sulfide, taurine, sodium hyaluronate, terephthalic acid, chamomile essential oil, peppermint essential oil and water for injection are stirred and mixed, and an appropriate amount of citrate buffer is added to adjust the pH to 5-7.5, and sodium chloride is added to adjust the osmotic pressure to 310mOsm / (Kg·H2O), and the mixture is filtered and sterilized, and packaged to obtain the product.
[0110] Test Example 1
[0111] In vitro antioxidant assay
[0112] Daily contact lens wear leads to excessive production of ROS free radicals, especially superoxide anions (O 2 ) accumulation, now the eye care composition containing ergothioneine prepared by Example 1-3 and Comparative Example 1-13 is subjected to antioxidant test.Superoxide anion is measured by pyrogallol autoxidation method, and hydroxyl radical scavenging experiment adopts Fenton colorimetry, and DPPH free radical scavenging method is the most widely used method for indirectly detecting the antioxidant capacity of measured material.The above reaction judges the antioxidant performance of measured material by detecting the change of absorbance.The result is shown in Table 1-3.
[0113] Table 1. 2 Inhibition rate results
[0114] Example <![CDATA[O 2 Inhibition rate / %]]> Hydroxyl free radical scavenging rate / % DPPH inhibition rate / % Example 1 99.5 65.4 99.4 Example 2 99.2 63.7 99.0 Example 3 99.3 62.5 99.1 Comparative Example 1 34.5 24.3 43.6 Comparative Example 2 33.6 20.9 40.9 Comparative Example 3 52.1 30.2 64.3 Comparative Example 4 38.2 22.1 42.2 Comparative Example 5 37.4 20.7 44.7 Comparative Example 6 31.9 25.7 41.6 Comparative Example 7 35.2 21.4 40.2 Comparative Example 8 47.1 29.8 63.7 Comparative Example 9 54.8 32.5 63.1 Comparative Example 10 61.5 34.7 67.2 Comparative Example 11 52.4 33.6 61.8 Comparative Example 12 31.6 20.3 43.4 Comparative Example 13 82.9 58.5 79.5
[0115] As shown in Table 1, the eye care composition containing thioneine prepared by the technical solution of the present invention has good antioxidant effect, which is significantly better than comparative example, and thioneine, taurine and terephthaloyl boric acid three have synergistic effect in improving antioxidant effect, especially under the specific ratio of the technical solution of the present invention, the antioxidant property of the eye care composition containing thioneine is significantly improved.
[0116] Test Example 2
[0117] Cytotoxicity assay
[0118] The concentration was 1×10 5 100 μL / well of corneal stromal cell suspension with a concentration of 1 cell / mL was added to a 96-well plate and incubated in 5% CO 2 , culture in a 37°C incubator for 24 hours and then aspirate the culture medium. Then, the eye care composition containing ergothioneine prepared in Examples 1-3 and Comparative Examples 1-13 and complete culture medium were added to the 96-well plate at a ratio of 1:10 and the cells were cultured for 24 hours, and the culture was continued in the incubator for 24 hours. The positive (10% DMSO), negative (complete cell culture fluid) control groups and the eye care composition containing ergothioneine prepared in Examples 1-3 and Comparative Examples 1-13 were all set up with 6 replicates. Add 20 μL / well MTT and continue incubation for 3 hours. Then add 100 μL DMSO and oscillate for 10 minutes. The absorbance value was measured at a wavelength of 570 nm on a microplate reader, and the cell activity was calculated:
[0119] Cell activity = (OD value of test wells + OD value of blank control wells) / OD value of negative control wells.
[0120] The results are shown in Table 2.
[0121] Table 2. Cytotoxicity test results
[0122]
[0123] As can be seen from the data in Table 2, the 24h corneal stromal cell survival rate of all products is above 99%, and the 72h corneal stromal cell survival rate is above 98%, indicating that the eye care composition containing ergothioneine prepared by the embodiment formula and the comparative example formula is safe and nontoxic to corneal stromal cells.
[0124] Test Example 3
[0125] Antibacterial effect
[0126] Using Escherichia coli, Staphylococcus aureus, Pseudomonas aeruginosa and Candida albicans as test bacteria, the antibacterial effects of the eye care compositions containing ergothioneine prepared in Examples 1-3 and Comparative Examples 1-13 on the four strains were tested.
[0127] Experimental bacterial suspension is prepared, and Pseudomonas aeruginosa, Staphylococcus aureus, Escherichia coli, and Candida albicans are cultivated with agar medium. Appropriate 0.9% sterile sodium chloride solution is added to elute the culture on agar surface, and bacterial suspension is moved to a sterile test tube, diluted with 0.9% sterile sodium chloride solution and made into a bacterial suspension that every 1mL contains bacteria count of about 108cfu. Take 0.5mL test bacterial suspension in a test tube, then add 0.5mL organic interfering substance (3% bovine serum albumin solution), mix, put in 20 ℃ ± 1 ℃ of water baths after 5min, draw respectively with sterile pipette above-described embodiment 1-3 and comparative example 1-13 prepared eye care composition containing ergothioneine each 4.0mL and inject wherein, mix rapidly and record immediately.
[0128] After the test bacteria interact with the samples of each embodiment and comparative example for each predetermined time, 0.5 mL of the test bacteria and sample mixture is respectively drawn and added to 4.5 mL of the sterilized neutralizer and mixed. After each tube of the test bacteria and sample mixture is added with the neutralizer for 10 minutes, 1.0 mL of the sample solution is respectively drawn, and the number of surviving bacteria is determined by the live bacteria culture counting method. Each tube of sample solution is inoculated with 2 plates. If the number of colonies growing on the plate is large, a series of 10-fold dilutions can be performed, and then live bacteria culture counting can be performed. At the same time, the diluent is used instead of the sample to perform a parallel test as a control.
[0129] All test samples were cultured in a 37°C incubator. The bacterial propagules were cultured for 48 hours to observe the final results; the bacterial spores were cultured for 72 hours to observe the final results. The test was repeated 3 times, and the number of viable bacteria in each group was calculated, and then the antibacterial rate was calculated according to the following formula:
[0130] Bacterial inhibition rate = (number of live bacteria in the control group - number of live bacteria in the test group) / number of live bacteria in the control group × 100%. The results are shown in Table 3.
[0131] Table 3. Antibacterial effect
[0132]
[0133]
[0134] As shown in Table 3, the eye care composition containing thioneine prepared by the technical solution of the present invention has good antibacterial effect, which is significantly better than the comparative example, and taurine and terephthaloyl boric acid have a synergistic effect in improving antioxidant effect, especially under the specific ratio of the technical solution of the present invention, the antibacterial effect of the eye care composition containing thioneine is significantly improved.
[0135] Test Example 4
[0136] In vivo experiments:
[0137] 1. Residence time experiment
[0138] 2% sodium fluorescein is added to the eye care composition containing thioneine prepared by Example 1-3 and Comparative Example 1-13, and fully mixed. Taking New Zealand rabbit as experimental subject, it is randomly divided into 16 groups, 6 in each group, and there is no significant difference in age and weight of each group of rabbits. One side eyelid of rabbit eye is pulled open, and the above-mentioned different eye care compositions containing thioneine 30 μ L are dripped respectively in rabbit eye, and rabbit eye is manually closed for 10s. Afterwards, every 2min is irradiated with ultraviolet light, and the strength of the continuous fluorescent layer on the corneal surface is observed. The time when the continuous fluorescent layer disappears is counted as the eye retention time. Continuously measured 3 times, averaging is the eye retention time, and the result is as shown in Table 4.
[0139] Table 4. Eye retention time
[0140]
[0141] As shown in Table 4, the eye care composition containing thioneine prepared by the technical solution of the present invention is compared with the eye care composition containing thioneine prepared by the comparative example, and its residence time significantly increases, indicating that the specific component and proportioning and preparation method of the technical solution of the present invention improve the bioavailability of the eye care composition containing thioneine.
[0142] 2. Animal Experiment on Dry Eye Syndrome
[0143] 1 Experimental Materials
[0144] 1.1 Animals:
[0145] 95 SPF BALB / c male mice, 6-8 weeks old, weighing (21±3) g, were placed in the animal room and fed adaptively for 1 week with free access to water. The temperature was (24±2)°C and the humidity was 47%.
[0146] 1.2 Methods of establishing animal models of dry eye
[0147] Five mice were selected as the blank group and injected with normal saline daily. The remaining 90 mice were modeled and all were dripped with 0.2% benzalkonium chloride solution to establish a benzalkonium chloride-induced dry eye mouse model, 5 μL / eye each time, once a day. After 6 weeks of eye drops, tear secretion and tear breakup time (BUT) were tested to determine the mouse model, and unqualified mice were eliminated.
[0148] Modeling results of 90 mice: 85 mice were successfully modeled, and 5 mice failed to model. The 85 mice with successful modeling were randomly divided into 17 groups (16 experimental groups, including Examples 1-3 and Comparative Examples 1-13) with 5 mice in each group, one of which was a model group.
[0149] 1.3 Administration:
[0150] In the blank group, each mouse received 0.2 mL of sterile saline in the left and right eyes twice a day;
[0151] Test groups 1-16 (corresponding to Examples 1-3 and Comparative Examples 1-13, respectively) were dripped into the left and right eyes of each mouse every day with 0.2 mL of the eye care composition containing ergothioneine prepared by Examples 1-3 and Comparative Examples 1-13, twice a day;
[0152] In the model group, 0.2 mL of sterile saline was dropped into the left and right eyes of each mouse twice a day;
[0153] Observe the indicators for 28 consecutive days.
[0154] 1.4 Observation indicators:
[0155] 1) Tear secretion
[0156] After modeling, the tear secretion volume of mice was tested using tear secretion test paper (Schirmer I test, SIT) to determine whether the model was established. After drug intervention, the tear secretion volume of mice was tested again using tear secretion test paper to determine the effect of the intervention drug on the tear secretion of mice.
[0157] 2) Tear film breakup time measurement
[0158] After modeling, the BUT of mice was observed by fluorescein staining to determine whether the model was established. After drug intervention, BUT was tested again to determine the effect of the intervention drug on the tear secretion of mice.
[0159] 3) Immunofluorescence was used to detect the expression levels of interleukin (IL) 1β, IL6, and tumor necrosis factor α (TNFα) in the corneal tissue of each group of mice. After 4 weeks of medication, the mice were killed by overdose of anesthesia, and the eyeballs were removed and quickly fixed in 4% paraformaldehyde for later immunofluorescence detection. The fixed eyeballs were removed, dehydrated by an automatic paraffin dehydrator, and then embedded, sliced, dewaxed, and baked. The antigens were repaired by heat repair method, blocked with 5% BSA, washed with PBS, and primary antibody and Alexa Fluor 488 labeled secondary antibody were added. Finally, the eyes were observed under a light microscope, and the average optical density values in 4 random fields were calculated for statistics.
[0160] 1.5 Statistical analysis:
[0161] SPSS 16.0 statistical software was used for analysis and processing, and the data were expressed as (x±s). One-way analysis of variance was used for comparison between groups. The results are shown in Table 5.
[0162] Table 5. Results of animal experiments on dry eye
[0163]
[0164] Note: Test example 1-3 corresponds to Example 1-3, and Test example 4-16 corresponds to Example 4-16;
[0165] Compared with the model group, **P<0.01; *P<0.05.
[0166] As can be obtained from Table 5 data, the eye care composition containing thioneine prepared by the technical solution of the present invention is compared with the eye care composition containing thioneine prepared by comparative example, and its anti-inflammatory property and moisture retention are significantly improved, illustrating that the specific component and proportioning and preparation method of the technical solution of the present invention improve the anti-inflammatory property and soothing property etc. of the eye care composition containing thioneine.
[0167] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.
Claims
1. An eye care composition containing ergothioneine, characterized in that, Contains the following ingredients: ergothioneine, taurine, sodium hyaluronate, plant essential oils, terephthalic acid, osmotic pressure regulator and water for injection.
2. The eye care composition containing ergothioneine according to claim 1, characterized in that, The mass ratio of ergothioneine, taurine and terephthaloylboric acid is 70-120:190-250:
1.
3. The eye care composition containing ergothioneine according to claim 1, characterized in that, The mass ratio of taurine, sodium hyaluronate and plant essential oil is 10-25:1-10:
1.
4. The eye care composition containing ergothioneine according to claim 1, characterized in that, The invention comprises the following components in parts by weight: 0.01-1 parts of ergothioneine, 0.1-5 parts of taurine, 0.05-0.4 parts of sodium hyaluronate, 0.03-0.06 parts of plant essential oil, 0.001-0.004 parts of terephthalic acid and 0.1-0.5 parts of osmotic pressure regulator, and the injection water is supplemented to 100 parts by weight.
5. The eye care composition containing ergothioneine according to claim 4, characterized in that, The invention comprises the following components in parts by weight: 0.25-0.42 parts of ergothioneine, 0.6-1.2 parts of taurine, 0.2-0.4 parts of sodium hyaluronate, 0.03-0.06 parts of plant essential oil, 0.001-0.004 parts of terephthalic acid and 0.1-0.5 parts of osmotic pressure regulator, and the injection water is supplemented to 100 parts by weight.
6. The eye care composition containing ergothioneine according to claim 5, characterized in that, The invention comprises the following components in parts by weight: 0.3-0.35 parts of ergothioneine, 0.7-0.8 parts of taurine, 0.22-0.3 parts of sodium hyaluronate, 0.04-0.05 parts of plant essential oil, 0.003-0.004 parts of terephthalic acid and 0.3-0.5 parts of osmotic pressure regulator, and the injection water is supplemented to 100 parts by weight.
7. The eye care composition containing ergothioneine according to claim 1, characterized in that, The eye care composition containing ergothioneine further comprises a pH regulator.
8. The eye care composition containing ergothioneine according to claim 1, characterized in that, The pH value of the eye care composition containing ergothioneine is 5-7.
5.
9. The eye care composition containing ergothioneine according to claim 7, characterized in that, The pH regulator is selected from at least one of a citrate buffer and a borate buffer.
10. The eye care composition containing ergothioneine according to claim 1, characterized in that, The plant essential oil is selected from at least one of rose essential oil, chamomile essential oil and peppermint essential oil.
11. The eye care composition containing ergothioneine according to claim 10, characterized in that, The plant essential oil is selected from at least one of chamomile essential oil and peppermint essential oil.
12. The eye care composition containing ergothioneine according to claim 11, characterized in that, The plant essential oils are chamomile essential oil and peppermint essential oil.
13. The eye care composition containing ergothioneine according to claim 12, characterized in that, The mass ratio of the chamomile essential oil to the peppermint essential oil is 1-6:2-4.
14. The eye care composition containing ergothioneine according to claim 1, characterized in that, The osmotic pressure regulator is selected from at least one of sodium chloride, potassium chloride, sorbitol, borax and boric acid.
15. The preparation method of the eye care composition containing ergothioneine according to any one of claims 1 to 14, characterized in that, The following steps are involved: S1: Mix sodium hyaluronate and water for injection to obtain solution A; S2: Solution A is mixed with taurine, ergothioneine and terephthaloylboric acid, and the pH is adjusted to 5-7.5 to obtain solution B; S3: Solution B is mixed with plant essential oil, and an osmotic pressure regulator is added to adjust the osmotic pressure to 250-350 mOsm / (Kg·H2O), and the mixture is filtered and sterilized, and packaged.
16. The preparation method according to claim 15, characterized in that: The mixing temperature of S1 is 75-85°C; The mixing temperature of S2 is 35-45°C; The mixing temperature in S3 is 30-35°C.
17. Use of the eye care composition containing ergothioneine according to any one of claims 1 to 14 in eye care.
Citation Information
Patent Citations
Contact lens care solution containing antioxidant substances and preparation method thereof
CN114410391A
Composition with antioxidant, moisturizing and lubricating effects and application thereof
CN114748611A
Ophthalmic anti-radiation composition as well as preparation method and application thereof
CN115068595A
Methods of treating microbial infection and inflammation
WO2019089878A1
Cited By
Multi-effect composition containing ergothioneine as well as preparation method and application thereof in eye products
CN120713930A
A multi-effect composition containing ergothioneine, its preparation method and application in eye products
CN120713930B
